---
title: "BANF1, Genome Stability, and Innate Immunity: Implications for Hematologic Malignancies"
id: "frontiers-in-immunology-15-banf1-at-the-crossroads-of-genome-stability-and-innate-immunity-emerging"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-banf1-at-the-crossroads-of-genome-stability-and-innate-immunity-emerging"
content_type: "clinical_feed_article"
specialty: "Hematology"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1990375"
published_at: "2026-10-07T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# BANF1, Genome Stability, and Innate Immunity: Implications for Hematologic Malignancies
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-banf1-at-the-crossroads-of-genome-stability-and-innate-immunity-emerging
- **Specialty:** [Hematology](https://medichelpline.com/clinical-feed/hematology.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1990375)
- **Published At:** 2026-10-07T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The provided source page contains site navigation and metadata for a Frontiers in Immunology review titled about **BANF1** and its roles at the intersection of **genome stability**, **innate immunity**, and hematologic cancers, but the main article text was not included in the source. - Details on BANF1 biology, molecular mechanisms, experimental results, clinical associations, or therapeutic implications were not reported in the supplied content. - The source lists the journal, article type (REVIEW), and partial citation information but does not provide abstract, introduction, results, discussion, figures, or references. - Because the article body is missing, no specific evidence, study outcomes, or author conclusions can be summarized from the source. - Readers interested in the topic should consult the full article at the journal site for primary details on **BANF1**, pathways linking DNA maintenance and innate immune sensing, and any reported links to **hematologic malignancies**. - The following clinical guide and section structure reflect reasonable expectations for a review on this subject but are explicitly labeled as not present in the source; any mechanistic or clinical statements below are framed as topics that would need verification in the full article.
## Clinical Analysis & Structured Key Points
Frontiers | BANF1 at the crossroads of genome stability and innate immunity: emerging implications for hematologic malignancies REVIEW article Front. Immunol. , 07 October 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1990375 Published in Frontiers in Immunology Cancer Immunity and Immunotherapy 7 impact factor 11.3 citescore Editor & Reviewers Edited by J H Jiancheng Hu Reviewed by L J Lei Jin W A Waseem AlZamzami Outline Figures and Tables Figure 1 View in article Figure 2 View in article Figure 3 View in article Table 1 Direct BANF1 mechanisms, measured phenotypes, and limits of inference. View in article Table 2 Hematologic evidence map: direct BANF1 findings versus candidate contexts. View in article Table 3 One integrated experimental matrix for future BANF1 validation. View in article REVIEW article Front. Immunol. , 07 October 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1990375 BANF1 at the crossroads of genome stability and innate immunity: emerging implications for hematologic malignancies X J Xia Jiang 1,2 Y Z Yihan Zhang 1,2 D C Dong Chen 1,2 F L Fenglin Li 1,2 H Z Haihui Zhuang 1,2 S L Shuangyue Li 1,2 R P Renzhi Pei 1,2 Y L Ying Lu 1,2 * 1. Department of Hematology, The Affiliated People’s Hospital of Ningbo University, Ningbo, China 2. Institute of Hematology, Ningbo University, Ningbo, China Article metrics View details Abstract Genomic instability and immune escape are linked features of hematologic malignancies, but the mechanisms that allow malignant cells to tolerate persistent nuclear and genotoxic stress while avoiding damaging DNA-sensing responses remain incompletely defined. Barrier-to-autointegration factor 1 (BANF1) is a small DNA-binding protein that bridges chromatin, couples it to nuclear-envelope proteins, supports postmitotic nuclear assembly and rupture repair, modulates several DNA-damage-response pathways, and restricts productive engagement of cyclic GMP-AMP synthase (cGAS) with self-DNA. Human BANF1 variants associated with progeroid disease and motor neuronopathy, together with functional studies in solid tumors, establish organism-level and cancer relevance, but they do not establish a selective blood-cancer dependency. Here, we integrate direct BANF1 evidence with disease-specific studies of replication stress, repair dependence, and innate DNA sensing in acute myeloid leukemia, T-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, multiple myeloma, myelodysplastic syndromes, and virus-associated lymphoid malignancies. The evidence supports a focused question: whether defined malignant hematopoietic states require BANF1 more than normal hematopoiesis, and which BANF1 function accounts for that difference. Direct hematologic evidence remains concentrated in gammaherpesvirus-associated models and concerns viral reactivation and innate signaling rather than a demonstrated lymphoma-survival dependency. We therefore distinguish direct perturbation evidence from related disease biology and from mechanistic hypotheses, emphasize that repair regulation is context dependent and that cGAS recruitment is not equivalent to cGAMP production, and critically assess survival evidence, pharmacologic tractability, and normal-cell safety. BANF1 therefore remains a mechanistically compelling candidate for disease-specific investigation in hematologic malignancies, with selectivity, signaling context, and normal-cell safety unresolved. 1 Introduction Genomic instability and immune escape are interdependent features of hematologic malignancies. Leukemic, lymphomatous, and plasma-cell neoplasms often arise under sustained proliferative pressure, replication stress, chromosome-segregation errors, and altered DNA-damage-response (DDR) programs. These processes fuel clonal evolution and treatment resistance, but excessive damage also threatens nuclear integrity, exposes self-DNA, and can trigger cell death or innate immune signaling. Malignant cells must therefore preserve sufficient genome and nuclear stability to proliferate while tolerating a high burden of endogenous and treatment-induced stress. This dependence on stress-buffering pathways is experimentally evident. T-cell acute lymphoblastic leukemia (T-ALL) can depend on CHK1 to limit replication-associated damage ( 1 ), and multiple myeloma (MM) shows an exploitable ATR dependence, including synergy between ATR inhibition and melphalan ( 2 ). Acute myeloid leukemia (AML) similarly contains replication-stress states that can be sensitized by CHK1 or ATR inhibition ( 3 , 4 ). Genome stress also intersects with innate immunity: pharmacologic STING activation can produce antileukemia immune responses in AML models ( 5 ), whereas bortezomib can engage cGAS-STING-associated immunogenic responses in MM ( 6 ). In contrast, chronic cGAS-STING-NLRP3 signaling in myelodysplastic syndromes (MDS) can contribute to ineffective hematopoiesis and inflammatory injury ( 7 , 8 ). Thus, the biological consequence of DNA sensing is not uniformly beneficial or harmful; it depends on disease, cell compartment, signal duration, and pathway competence. BANF1, also called BAF and distinct from the SWI/SNF BAF complex, is relevant because it sits at the interface of these problems. BANF1 forms DNA-binding dimers, links chromatin to LEM-domain proteins and lamins, supports postmitotic nuclear assembly and nuclear-envelope repair, modulates selected repair enzymes, and restrains productive cGAS engagement with self-DNA ( 9 – 20 ). These functions make BANF1 more than a structural nuclear-envelope component, but they also make simplistic therapeutic assumptions unsafe: the same protein can preserve nuclear integrity, restrain PARP1 or DNA-PK activity, support MRN-associated signaling in another context, and raise the threshold for innate DNA sensing. Human genetics strengthens the biological rationale. Homozygous BANF1 p.Ala12Thr (A12T) causes Nestor-Guillermo progeria syndrome, and patient-cell work links this variant to weakened lamin A/C engagement and mechanically fragile rupture repair ( 21 , 22 ). A distinct de novo heterozygous p.Gly16Arg (G16R) variant has been associated with dominant motor neuronopathy and altered BANF1 conformational behavior and DNA binding ( 23 ). These variants demonstrate organism-level consequences of altered BANF1 function, but they are not evidence of leukemia predisposition and do not identify an anticancer therapeutic window. Cancer relevance is supported by direct perturbation in solid-tumor models. BANF1 is increased in selected gastric and colorectal cancer settings, and genetic manipulation can alter growth, invasion, survival, or treatment response ( 24 – 26 ). Tumor-intrinsic BANF1 deletion can also enhance cGAS-STING-dependent antitumor immunity and improve the effect of PD-1 blockade in melanoma and colorectal models ( 27 ). These studies justify investigation in blood cancer, but none demonstrates that malignant hematopoietic cells depend more strongly on BANF1 than normal hematopoietic cells. The central question for this review is therefore whether a defined malignant hematopoietic state requires BANF1 more than normal hematopoiesis does, and whether any differential requirement is structural, repair-related, or immune-mediated. To keep that question explicit, we distinguish three evidence levels throughout: direct BANF1 perturbation in the stated model; related hematologic biology without BANF1 perturbation; and a proposed mechanistic connection that remains to be tested. This is a narrative review rather than a systematic review or a new patient-cohort analysis. Accordingly, the discussion proceeds from biological significance and human disease relevance through a condensed mechanistic foundation, DNA-sensing biology, direct virus-associated hematologic evidence, candidate hematologic contexts, critical synthesis, and a single Future Directions framework. Gene symbols are italicized when they refer to genes or defined genetic lesions, whereas protein and pathway names are shown in roman type; BANF1 denotes the protein unless the gene is explicitly specified. 2 Mechanistic foundation of BANF1 function 2.1 DNA bridging, nuclear-envelope coupling, and state control BANF1 is a small DNA-binding homodimer whose opposing DNA-binding surfaces permit cross-bridging of separate DNA duplexes ( 9 ). Structural work shows that BANF1 can engage LEM-domain proteins such as emerin while also interacting with DNA, and ternary structural studies define a lamin A/C-BANF1-emerin interface that couples chromatin to nuclear-envelope components ( 10 , 11 ). More recent cryo-electron microscopy extends this architecture to nucleosome-associated BANF1-lamin A/C assemblies ( 12 ). These findings support a multivalent chromatin-nuclear-envelope scaffold rather than a single linear interaction chain. BANF1 function is strongly state dependent. VRK1 phosphorylates nucleoplasmic and mitotic BANF1, whereas lamin-associated VRK2A regulates a nuclear-envelope-associated pool; N-terminal phosphorylation reduces DNA binding ( 28 , 29 ). ANKLE2-associated PP2A and PP4C support dephosphorylation in defined contexts, and K6-linked SUMOylation promotes nuclear retention, replication competence, and nuclear integrity ( 30 – 32 ). Expression alone is therefore an incomplete proxy for BANF1 activity. Importantly, manipulation of a kinase or phosphatase is not equivalent to BANF1 depletion: for example, reducing VRK activity can shift BANF1 toward a more DNA-bound state rather than reproducing loss of the protein. The structural interfaces also explain why BANF1 should not be treated as a binary on/off factor. DNA binding, LEM-domain engagement, lamin association, phosphorylation, and nuclear retention can vary independently, so the same total protein abundance can correspond to different functional states. The A12T and G16R human variants reinforce this point from different directions: altered partner engagement and altered DNA-binding behavior can both be pathogenic ( 22 , 23 ). For hematologic studies, measurements of total BANF1 should therefore be accompanied, where feasible, by localization and state-sensitive readouts rather than interpreted as a direct measure of functional activity. 2.2 Postmitotic assembly and interphase rupture repair The strongest human-cell evidence for a structural BANF1 requirement comes from postmitotic nuclear assembly. BANF1-mediated DNA cross-bridging organizes the anaphase chromosome mass into a single nucleus. Acute BANF1 loss during mitotic exit permits abnormal membrane penetration between chromosomes and produces fragmented or lobulated nuclear assemblies ( 13 ). This is a measured nuclear-assembly phenotype; it should not be re-labeled as evidence that blood cancers are selectively BANF1 dependent. Single-nucleus formation is relevant beyond nuclear morphology because material excluded from the primary daughter nucleus can be packaged into micronuclei, where replication and envelope integrity are frequently abnormal. BANF1-mediated chromosome enclosure therefore acts upstream of several later stress phenotypes, including micronucleus formation and access of DNA sensors to aberrant chromatin. However, this does not mean that every defect in postmitotic enclosure produces productive cGAS signaling; the downstream sensing step remains conditional and is considered separately below. BANF1 also functions during interphase nuclear-envelope rupture. Exposed chromatin rapidly recruits predominantly nonphosphorylated BANF1, which promotes recruitment of LEM-domain and membrane components ( 14 ). The quantitative requirement is model dependent: BANF1 loss can prevent efficient barrier restoration or prolong rupture, especially for larger defects, whereas an A12T background illustrates that simple resealing and durable repair are distinct because repaired regions can remain mechanically fragile and prone to re-rupture ( 14 , 15 , 22 ). LEM2/CHMP7 and ESCRT-associated studies further indicate partially overlapping closure pathways rather than a universal BANF1-LEM2-CHMP7 linear cascade ( 33 , 34 ). Mechanical rupture is relevant to both cancer and normal hematopoiesis. Constricted migration disrupts nuclei in invasive tumor cells, and strong deformation can likewise cause nuclear-envelope rupture and DNA damage in migratory immune cells ( 35 , 36 ). This dual relevance is important for translation: a mechanism that destabilizes tumor nuclei may also compromise physiologically migratory leukocytes. Any future claim of tumor selectivity must therefore include normal hematopoietic and immune-cell controls rather than relying only on established cancer cell lines. 2.3 Context-dependent regulation of DNA repair BANF1 participates in several DDR pathways, but the direction of its effect varies. After oxidative damage, BANF1 binds PARP1 and restrains PARP1 catalytic activity; increasing BANF1 can reduce PARylation and impair repair of oxidative lesions in the tested systems ( 16 ). In a distinct double-strand-break setting, BANF1 directly restrains DNA-PKcs. BANF1 depletion increases non-homologous end joining and reduces homologous recombination, indicating that BANF1 influences repair-pathway allocation rather than simply increasing total repair capacity ( 17 ). BANF1 is also linked to replication competence through K6-linked SUMOylation. SUMOylation promotes nuclear retention, association with lamin A/C and PCNA, and normal DNA replication, whereas disruption of this cycle produces replication failure and abnormal nuclear architecture ( 32 ). This observation provides a mechanistic bridge between S-phase stress and later mitotic or nuclear-envelope phenotypes without establishing BANF1 as a canonical replisome component. It also helps explain why the phenotype of BANF1 perturbation may depend strongly on cell-cycle state. A different phenotype is seen in a hepatocellular carcinoma stiffness model, in which SDC4/PKD2 signaling promotes PP2A-dependent nuclear localization of BANF1, association with MRE11, MRN-complex assembly, and ATM/CHK2 signaling ( 18 ). That pathway has not been established in marrow-resident malignancies. The apparently opposing PARP1, DNA-PK, and MRN findings therefore should not be averaged into a single ‘pro-repair’ designation. Lesion type, cell-cycle state, localization, partner engagement, and tissue context determine the observed effect. Figure 1 and Table 1 summarize these direct mechanisms, the measured cellular phenotype, and where hematologic extrapolation begins. Figure 1 BANF1 architecture, state control, and evidence-graded functional outputs. (A) BANF1 forms a DNA-bridging homodimer and engages LEM-domain proteins, lamin A/C, and nucleosomal chromatin ( 9 – 12 ). The schematic uses simplified interaction modules rather than protein-fold or binding-geometry models. (B) BANF1 state is regulated by compartment-specific phosphorylation/dephosphorylation and K6-linked SUMOylation: VRK1 preferentially regulates nucleoplasmic/mitotic BANF1, VRK2A an envelope-associated pool, and PP4C and ANKLE2-associated PP2A promote dephosphorylation; SUMOylation supports nuclear retention and replication competence ( 28 – 32 ). (C) Direct mechanisms are linked first to the cellular phenotype actually measured and only then, by dashed connectors, to proposed hematologic contexts. DNA cross-bridging supports single-nucleus assembly ( 9 , 13 ); LEM/lamin engagement contributes to rupture repair ( 14 , 15 , 22 ); and DNA-binding-competent BANF1 limits productive cGAS catalysis ( 19 ). The right-hand disease contexts are hypotheses, not established BANF1 requirements. Repair effects are context dependent: BANF1 restrains PARP1 and DNA-PKcs but supports MRN-associated signaling in a distinct HCC model ( 16 – 18 ). HCC, hepatocellular carcinoma; LEM, LAP2-emerin-MAN1; MRN, MRE11-RAD50-NBS1 complex. Table 1 Mechanism/model Directly supported finding Boundary of the inference References DNA bridging and nuclear assembly; biochemical and human-cell systems DNA cross-bridging organizes chromosome enclosure; acute mitotic loss produces fragmented nuclei. A nuclear-assembly requirement in these systems is not evidence of selective blood-cancer dependence. ( 9 , 13 ) LEM/lamin coupling and rupture repair; cellular and patient-derived systems BANF1 recruits repair components; A12T weakens lamin engagement and repair robustness. Barrier closure, repair duration, and resistance to re-rupture are distinct endpoints. ( 10 , 11 , 14 , 15 , 22 ) State regulation; kinase, phosphatase, and SUMO studies Phosphorylation, dephosphorylation, and SUMOylation alter DNA engagement, localization, or replication competence. Manipulation of a regulator is not equivalent to BANF1 depletion and may have BANF1-independent effects. ( 28 – 32 ) Repair regulation; oxidative lesions, DSBs, and HCC stiffness models BANF1 restrains PARP1 and DNA-PKcs; nuclear BANF1 supports MRN-associated signaling in the HCC model. Direction varies with pathway and model. These findings do not define a universal pro-repair function. ( 16 – 18 ) cGAS restriction and bridge stability; cellular and reconstituted systems BANF1 destabilizes productive cGAS–DNA engagement and can limit bridge-associated inflammatory responses. cGAS recruitment is not itself evidence of cGAMP synthesis; no direct BANF1-to-STING inhibitory interaction is inferred. ( 19 , 20 , 43 ) Direct BANF1 mechanisms, measured phenotypes, and limits of inference. Direct evidence is restricted to the stated model and endpoint. DSB, DNA double-strand break; HCC, hepatocellular carcinoma; MRN, MRE11-RAD50-NBS1 complex. This table summarizes evidence, not proposed experiments. 3 BANF1 and innate DNA sensing: access is not activation 3.1 Direct competition with cGAS BANF1 provides a second layer of protection against inappropriate sensing of genomic self-DNA. In cellular, purified-protein, and single-molecule experiments, DNA-binding-competent BANF1 limits cGAMP production by competing with cGAS for DNA and shortening the residence time of cGAS on DNA, thereby reducing formation of stable, catalytically productive assemblies ( 19 ). A LEM-binding-defective BANF1 mutant retains substantial immune-restraining activity, whereas a DNA-binding-defective mutant does not, placing the principal checkpoint at the substrate-sensor interface rather than at STING itself. BANF1 can also influence the amount of DNA available for sensing. An independent study found increased basal cytosolic DNA of nuclear and mitochondrial origin and cGAS-STING-dependent signaling after BANF1 loss ( 20 ). These data support two related but separable functions: BANF1 can affect DNA compartmentalization and can reduce the probability that accessible DNA supports productive cGAS catalysis. Neither mechanism implies a direct BANF1-STING inhibitory interaction. This distinction between access and catalysis is particularly important in cancer biology. A damaged or ruptured nucleus may expose DNA, and cGAS may even localize to that substrate, yet the biochemical threshold for cGAMP synthesis can remain unmet. BANF1 therefore acts most defensibly as a regulator of productive sensor engagement rather than as a generic suppressor of all DNA-triggered inflammation. That framing also avoids conflating direct cGAS competition with downstream STING biology, which can differ among cell types and malignancies. 3.2 Micronuclei, chromatin bridges, and context-dependent signaling Micronuclear rupture illustrates why access and activation must be separated. Early studies connected micronuclei with cGAS recruitment and inflammatory signaling ( 37 , 38 ), but later work showed that micronuclei generated by irradiation, replication stress, or chromosome-segregation errors can recruit cGAS without detectable cGAMP production or downstream STING-TBK1-IRF3 a
## Related Clinical Research

- [Obesity-associated inflammation and cancer: mechanisms linking adipose immune changes to tumor risk](https://medichelpline.com/clinical-feed/frontiers-in-immunology-6-obesity-associated-inflammation-and-cancer-molecular-mechanisms-evidence-gaps.md)
- [Inferring tumor kinetics from single routine H&E biopsies to run virtual radiotherapy trials](https://medichelpline.com/clinical-feed/medrxiv-9-effective-tumor-kinetics-inferred-from-single-routine-h-e-biopsies-enable.md)
- [Arginine supplements and immune recognition: mouse study links arginine to improved cancer and vir](https://medichelpline.com/clinical-feed/medical-news-today-0-could-arginine-supplements-help-boost-immune-responses-to-cancer-viruses.md)
- [FTO's Role in Cancer: Immune Evasion and Therapeutic Resistance Insights](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-reader-dependent-functional-duality-of-fto-a-context-switching-node-at-the.md)
- [CBC-derived inflammatory indices in colorectal cancer: diagnostic and prognostic head-to-head anal](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-complete-blood-count-derived-inflammation-indices-in-colorectal-cancer-head-to.md)

## Navigation
- [← Back to Hematology Feed](https://medichelpline.com/clinical-feed/hematology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.